繁體
简体中文
繁體中文

SerenityShares Impact ETF ICAN 深 滬

已收盤 03-19 16:00:00 美东时间

28.485

0.000

0.00%

华盛通華盛通
立即下載
  • 最 高--
  • 今 開--
  • 成交量 0股
  • 最 低 --
  • 昨 收 28.485
  • 總市值 427.00万
  • 52周最高 30.00
  • 市盈率 靜 --
  • 換手率 0.00%
  • 52周最低 24.127
  • 委 比 0.00%
  • 總股本 14.99万
  • 歷史最高 30.00
  • 量 比 0
  • 振 幅 0.00%
  • 歷史最低 24.127
  • 每 手 1
  • 風險率 0.00%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • FLEXIBLE SOLUTIONS INTERNATIONAL DELAYS RELEASE OF FINANCIALS

    Flexible Solutions International, Inc. (FSI) has announced a delay in releasing its Q3 2026 financial statements due to its auditor requiring additional time to review intangible asset values. The company, which develops and manufactures biodegradable polymers and environmental technologies, will release the financials and details of a conference call once the audit is complete. FSI also operates in the food and nutrition supplement markets and m...

    11-16 21:00

  • American Battery Technology Company Announces First Quarter FY27 Financial Results Including 83% Year-Over-Year Revenue Growth

    American Battery Technology Company (ABTC) reported a 83% increase in revenue to $1.7 million for Q1 FY27, with $43.4 million in cash and zero debt. The company secured a $100 million license for exporting recycled black mass and achieved a major milestone with federal permitting for its Tonopah Flats Lithium Project, one of the largest U.S. lithium resources. ABTC also completed baseline studies for NEPA review and initiated a Definitive Feasibi...

    11-13 14:00

  • Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

    Perspective Therapeutics presented promising data on their Phase 1/2a trial of [<sup>212</sup>Pb]VMT-α-NET for unresectable or metastatic SSTR2-positive neuroendocrine tumors (NETs) at the NANETS 2026 Symposium. The study showed durable disease control, with a 95% disease control rate across all cohorts and a 75% progression-free survival at 18 months in GEP-NET patients whose target lesions express SSTR2. Objective response rates were 37% in Coh...

    11-06 01:10

  • Strawberry Fields Reit Announces Third Quarter 2026 Operating Results

    Strawberry Fields REIT reported Q3 2026 operating results, highlighting 100% collection of contractual rents and two property acquisitions totaling $25.4 million. FFO was $(3.6) million for the quarter, down from $20.7 million in Q3 2025, while AFFO rose to $18.8 million from $18.1 million. Year-to-date FFO was $37.6 million, down from $58.9 million in 2025, with AFFO at $55.9 million versus $53.4 million. The company attributes the decline in ne...

    11-05 22:00

  • DDC Founder and CEO's Letter to Shareholders

    DDC Enterprise Limited (NYSE American: DDC) launched its Series A 13.5% Perpetual Preferred Shares (SVOR), trading on NYSE American, with a stated value of $25.00 per share and a cumulative dividend of 13.5% annually, paid daily. The company also outlined plans to retire its outstanding convertible note, allocating up to 20% of offering proceeds toward this goal. DDC emphasized its Bitcoin treasury strategy as a long-term reserve asset and focuse...

    11-05 14:57

  • Birchtech Corp. to Host Third Quarter 2026 Earnings Call on November 12 at 5:00 p.m. Eastern Time

    Birchtech Corp. announced the release of its third quarter 2026 financial results on November 12, 2026, after market close. Management will host an investor conference call at 5:00 p.m. Eastern time on the same day to discuss the results and provide a corporate update. Participants can join via phone or webcast, with dial-in numbers and a conference ID provided. A playback of the call will be available until December 3, 2026, and a webcast replay...

    10-29 12:31

  • Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto

    Kyverna Therapeutics announced positive one-year data from the KYSA-8 trial of miv-cel, a CD19 CAR T-cell therapy, for stiff person syndrome (SPS). The trial showed significant and sustained improvements across all primary and secondary endpoints, with patients experiencing reduced disability, improved mobility, and freedom from chronic immunotherapies. Miv-cel demonstrated a strong safety profile with no high-grade cytokine release syndrome or n...

    10-21 11:15

  • FSI ANNOUNCES THIRD QUARTER 2026 REVENUE

    Flexible Solutions International, Inc. (NYSE-AMERICAN: FSI) reported a 36% year-over-year increase in Q3 2026 revenue, rising to $14.35 million from $10.56 million in Q3 2025. The growth was attributed to full operations at the Panama factory, strong performance in the ENP division, and progress in food-grade production. Full financial results will be released on November 13, 2026, with a conference call scheduled for November 16, 2026.

    10-19 13:00

  • B2Gold Third Quarter 2026 Results – Conference Call Details

    B2Gold Corp. will release its third quarter 2026 financial and operational results on November 4, 2026, after North American markets close. A conference call to discuss the results will be held on November 5, 2026, at 9:00 am PCT / 11:00 am ET. Participants can join via toll-free numbers, an international line, or a webcast link. A replay of the call will be available for two weeks. B2Gold is an international gold producer with operations in Cana...

    10-14 21:30

  • HHS advisors to discuss boosting funding for autism care

    A panel of advisors to HHS is meeting Thursday to discuss a draft plan that would significantly increase funding for medical care and other support for those with autism. Earlier this year, the Intera...

    08-27 23:02